Alnylam’s vision is to harness the potential of RNAi (RNA interference) therapeutics to transform the lives of people living with diseases for which there are limited or inadequate treatment options. Their pioneering work has delivered the world’s first and only approved RNAi therapeutics—ONPATTRO® (patisiran) in 2018, GIVLAARI® (givosiran) in 2019, OXLUMO® (lumasiran) in 2020, and AMVUTTRA® (vutrisiran) in 2022. Alnylam have pipeline RNAi-based medicines in four therapeutic areas: genetic medicines, cardio-metabolic diseases, infectious diseases, and central nervous system (CNS) and ocular diseases.